Markets:

Overview

News

Currencies

International

Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

43.65 +1.46 (+3.45%)

Streaming Delayed Price Updated: 12:41 PM EDT, Jun 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

99 100 Next >

AI Unleashes a New Era in Cell and Gene Therapy: A Quarter Century Update Reveals Transformative Potential

November 04, 2025

The burgeoning fields of cell and gene therapy (CGT) are on the cusp of a profound revolution, driven by the relentless advancements in artificial intelligence. This transformative impact was a central...

Via TokenRing AI

Topics Artificial Intelligence

Novo, Pfizer Are Battling To Buy The Future Of Weight-Loss — But Viking Already Owns It ↗

November 04, 2025

Viking Global's $45 million investment in Metsera, a biotech company is caught in a bidding war between Pfizer and Novo Nordisk.

Via Benzinga

Eli Lilly, Novo Nordisk Stocks Rise on Reported $149 Obesity Drug Deal with White House ↗

November 04, 2025

Eli Lilly and Company (NYSE:LLY) shares are trading slightly lower on Tuesday after its previous gains following reports indicating the company is close to finalizing a White House agreement to provide...

Via Benzinga

An Overview of Novo Nordisk's Earnings ↗

November 04, 2025

Via Benzinga

Novo Nordisk Q3 Preview: Analysts See Profit Drop As Obesity Market Cools, Pfizer Tensions Rise ↗

November 04, 2025

Via Stocktwits

The Battle For Metsera Acquisition Heats Up As Pfizer Files A Second Lawsuit ↗

November 03, 2025

Via Stocktwits

Pfizer, Novo Nordisk Intensify Fight For Metsera As Buyout Offers Continue To Climb ↗

November 04, 2025

Novo Nordisk boosts its Metsera bid to $62.20 per share, valuing the company at $10 billion and outbidding Pfizer in the escalating takeover fight.

Via Benzinga

Novo Sweetens Its Bid For Metsera, Pledging Up To $10 Billion ↗

November 04, 2025

Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked bid.

Via Investor's Business Daily

Metsera Gets Revised Bids From Pfizer, Novo Nordisk: Here’s Why It Matters ↗

November 04, 2025

Metsera said that it would be entitled to terminate its merger agreement with Pfizer if Novo’s proposal continues to be superior.

Via Stocktwits

Should You Buy Novo Nordisk Stock Before the Huge Investor Update? ↗

November 04, 2025

The company is preparing to launch a more convenient form of its weight loss treatment that has investors excited.

Via The Motley Fool

Pfizer Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts ↗

November 04, 2025

Via Benzinga

Retail Investors Now Expect Viking Therapeutics To Bag A Deal After Novo Nordisk, Pfizer Engage In A Bidding War For Rival Metsera ↗

October 30, 2025

Via Stocktwits

Hims & Hers Health Stock Jumps After-Hours As Q3 Growth, Novo Nordisk Talks Fuel Bullish Retail Bets ↗

November 03, 2025

Revenue rose 49% year-over-year to nearly $600 million, while net income reached $15.8 million and adjusted EBITDA climbed 53% to $78.4 million.

Via Stocktwits

Topics Earnings

Hims & Hers Health (HIMS) Surges After Hours on Robust Q3 and Renewed Novo Nordisk (NVO) Wegovy Talks

November 03, 2025

Hims & Hers Health (NYSE: HIMS) became a significant after-hours mover on Monday, November 3, 2025, following the release of its third-quarter 2025 financial results and the pivotal announcement of...

Via MarketMinute

Topics Artificial Intelligence Economy

Hims Says It's Negotiating A New Deal With Novo Nordisk; Shares Surge ↗

November 03, 2025

Hims & Hers Health said late Monday it's in discussions with Novo Nordisk to sell Wegovy shots. The news buoyed Hims stock.

Via Investor's Business Daily

Hims & Hers Stock Pops After Q3 Earnings: Here's Why ↗

November 03, 2025

Here's a look at the Q3 earnings report from Hims & Hers Health.

Via Benzinga

Did Novo Nordisk Just Say "Checkmate" to Pfizer? ↗

November 03, 2025

These two leading drugmakers are fighting over a promising GLP-1 candidate.

Via The Motley Fool

Topics Intellectual Property

Metsera Calls Pfizer's Claims 'Nonsense' In Latest Buyout Battle Salvo ↗

November 03, 2025

Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.

Via Investor's Business Daily

Topics Economy Lawsuit

Pfizer Accuses Novo Nordisk Of Antitrust Violations In Metsera Takeover Battle ↗

November 03, 2025

Pfizer sues Metsera and Novo Nordisk, alleging breach of contract and antitrust violations over a rival $9 billion bid challenging its $4.9 billion merger deal.

Via Benzinga

Topics Lawsuit

2 Beaten-Down Stocks That Could Be About to Rally ↗

November 03, 2025

It would be best to get in before the rest of the market pounces on these opportunities.

Via The Motley Fool

Novo Nordisk A/S (NYSE:NVO): A Top Dividend Stock with Strong Profitability and Financial Health ↗

November 03, 2025

Novo Nordisk (NVO) is a top dividend stock with a 3.6% yield, strong growth, and a sustainable payout backed by exceptional profitability and financial health.

Via Chartmill

Should You Buy Viking Therapeutics Before Nov. 5? ↗

November 02, 2025

Viking's stock surged in one trading session after a positive clinical trial report last year.

Via The Motley Fool

Is It Time to Dump Your Shares of Pfizer? ↗

November 02, 2025

Pfizer stock has dropped 50% over the past three years.

Via The Motley Fool

Topics Intellectual Property

AI Unleashes a New Era: Biopharma’s Accelerated Revolution and the Rise of TechBio

November 01, 2025

The biopharmaceutical industry is undergoing an immediate and profound transformation, as Artificial Intelligence (AI) rapidly compresses timelines, drastically reduces costs, and significantly...

Via TokenRing AI

Topics Animal Testing Artificial Intelligence Economy

Pfizer Sues Novo Nordisk And Metsera To Block The Proposed $6.5 Billion Deal ↗

October 31, 2025

Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller company.

Via Investor's Business Daily

Topics Law Enforcement Lawsuit

Viking Therapeutics Stock Powers Toward Best Month Of The Year — Wall Street, Retail Bulls Fired Up On Obesity Drug Promise ↗

October 31, 2025

Traders on Stocktwits linked Novo Nordisk’s renewed bid for Metsera to competition from Viking’s obesity drug VK2735, fueling further optimism.

Via Stocktwits

Eli Lilly Extends Lead In $150B Obesity Drug Race As Novo, Pfizer Clash — Here's How ETFs Stand To Gain ↗

October 30, 2025

As Eli Lilly, Novo Nordisk, and Pfizer battle for dominance in the obesity-drug market, these ETFs are offering exposure to the GLP-1 gold rush.

Via Benzinga

Topics ETFs

10 Health Care Stocks Whale Activity In Today's Session ↗

October 30, 2025

Via Benzinga

Novo Nordisk Kicks Off Bloody Battle With Pfizer, Bidding $6.5 Billion On Metsera ↗

October 30, 2025

Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.

Via Investor's Business Daily

Topics Economy Government

Pfizer Blasts Novo Nordisk's $9 Billion Counteroffer For Metsera As 'Reckless' ↗

October 30, 2025

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and potential legal action.

Via Benzinga

< Previous 1 2

...

16 17 18 19 20 21 22 23 24

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.